Business Context and Reporting Period
Company: Corniche Group Incorporated (Note: Input metadata referenced "Lisata Therapeutics," but the filing text identifies the registrant as Corniche Group Incorporated).
Reporting Period: Fiscal year ended December 31, 2001.
Current Operations: The Company operates an internet-based business selling extended warranties and service contracts via WarrantySuperstore.com. It does not bear the economic risk of claims, which are covered by appointed insurance carriers.
Discontinued Operations: The Company sold its reinsurance subsidiary, Stamford Insurance Company Limited, on April 30, 2001, for $372,000, recording a loss of approximately $479,000 on the sale.
Key Financial Metrics
| Metric | 2001 | 2000 |
|---|---|---|
| Earned Revenues | $107,447 | $27,175 |
| Gross Profit | $36,773 | $(6,164) |
| Operating Loss | $(1,606,101) | $(2,516,656) |
| Net Loss (Attributable to Common) | $(2,080,714) | $(2,075,376) |
| Loss Per Share (Basic/Diluted) | $(0.09) | $(0.14) |
| Cash Used in Operating Activities | $(373,843) | $(2,327,046) |
| Total Assets | $1,836,289 | $3,757,444 |
| Working Capital | $1,084,881 | $2,078,684 |
| Accumulated Deficit | $(8,486,445) | $(6,405,731) |
Liquidity: As of December 31, 2001, the Company held $51,268 in cash and cash equivalents and $1,503,374 in marketable securities (U.S. Treasury Bills and Federal Home Loan Mortgage notes).
Material Changes vs. Prior Period
- Revenue Growth: Earned revenues increased from $27,175 in 2000 to $107,447 in 2001, driven by the expansion of internet warranty sales.
- Expense Reduction: Selling, general, and administrative expenses decreased by 34.5% (from $2.51M to $1.64M), primarily due to a significant reduction in advertising costs ($1.03M decrease) as the Company shifted from banner ads to strategic partnerships.
- Impairment Charge: The Company recorded a non-cash impairment charge of $305,333 in Q4 2001 related to the write-off of unamortized capitalized software due to uncertainty regarding the future of the warranty business.
- Discontinued Operations: The sale of the Stamford subsidiary resulted in a $479,244 loss on disposal, contrasting with the $269,257 income from discontinued operations in 2000.
Outlook, Risks, and Unusual Items
StrandTek Transaction (Material Subsequent Event)
On January 7, 2002, the Company entered into an agreement to acquire StrandTek International, Inc., a manufacturer of melt-blown polypropylene insulation. Upon consummation (expected April 2002):
- StrandTek will become a majority-owned subsidiary.
- Current Corniche management will resign; StrandTek management will take control.
- The transaction is contingent on securing approximately $11 million in financing via a private placement.
- Current shareholders will be diluted significantly; StrandTek principals will receive approximately 35.2 million shares of Corniche Common Stock and convertible preferred stock.
Risks and Contingencies
- Going Concern: The independent auditors (Travis, Wolff & Company) have expressed substantial doubt about the Company's ability to continue as a going concern due to the pending acquisition and the need for financing.
- Business Uncertainty: No decision has been made regarding the future of the existing warranty business; it may be sold or terminated post-acquisition.
- Accumulated Deficit: The Company has an accumulated deficit of approximately $8.5 million and expects to continue incurring losses.
Investor Verification Checklist
- Transaction Status: Verify if the $11 million private placement financing for the StrandTek acquisition has been secured and if the deal closed as expected in April 2002.
- Capital Structure: Confirm the final share count and dilution impact resulting from the issuance of Series C and Series D Preferred Stock and Common Stock to StrandTek principals.
- Going Concern: Assess the Company's liquidity position post-transaction, given the substantial accumulated deficit and reliance on the new business for future cash flow.
- Warranty Business: Determine if the existing warranty business was sold, terminated, or retained following the change in control.
- StrandTek Performance: Review StrandTek's standalone financials (referenced in their own 10-K/10-Q) to evaluate the viability of the new core business, noting their history of significant operating losses.